New combo attack: CAR T-Cells plus radiation takes on tough lymphoma

NCT ID NCT06043323

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether combining a CAR T-cell therapy (axicabtagene ciloleucel) with radiation therapy is safe for people with follicular lymphoma that has returned or not responded to at least two prior treatments. About 20 adults will receive the treatment, and researchers will monitor side effects closely. The goal is to see if this combination can be a new option for hard-to-treat cases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: axicabtagene ciloleucel (CAR T-cell therapy)
What this could lead to: If successful, this combination could offer a new treatment option for people with follicular lymphoma that has stopped responding to standard therapies.
What could go wrong: This is a small, early-phase trial (20 people) focused on safety, not yet proven to work. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.